气功锻炼与穴位按摩康复方案对重症新型冠状病毒肺炎住院患者肺功能及呼吸道症状的影响：一项随机对照试验
Effect of qigong exercise and acupressure rehabilitation program on pulmonary function and respiratory symptoms in patients hospitalized with severe COVID-19: a randomized controlled trial.
作者信息
Liu Shu-Ting, Zhan Chao, Ma Yun-Jing, Guo Chao-Yang, Chen Wei, Fang Xiao-Ming, Fang Lei
机构信息
Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Huangshi Hospital of Traditional Chinese Medicine, Hubei, China.
出版信息
Integr Med Res. 2021;10(Suppl):100796. doi: 10.1016/j.imr.2021.100796. Epub 2021 Oct 29.
BACKGROUND
There are several effective complementary and integrative therapies for patients with severe COVID-19. The trial aims to evaluate the efficacy and advantages of the qigong exercise and acupressure rehabilitation program (QARP) for treating patients with severe COVID-19.
METHODS
A total of 128 patients with COVID-19 aged 20 to 80 years were recruited and randomly allocated in a 1:1 ratio to receive QARP plus standard therapies or standard therapies alone. QARP consisted of acupressure therapy and qigong exercise (). The primary outcome was measured with the modified Medical Research Council (mMRC) dyspnea scale, and the secondary outcomes included the modified Borg dyspnea scale (MBS), fatigue Scale-14 (FS-14), patient health questionnaire-9 scale (PHQ-9), duration of respiratory symptoms, and vital signs.
RESULTS
In total, 128 patients completed the clinical trial. The QARP group and standard therapies group showed significant improvements in vital signs (except blood pressure) and clinical scales compared with baseline (p<0.05). The QARP group also showed more significant improvement in the mMRC dyspnea scale (-1.8 [-2.1, -1.6], p=0.018) and modified Borg dyspnea scale (-3.7 [95% confidence intervals (CI) -4.3, -3.1], p=0.045). The duration of cough was 14.3 days (95% CI 12.6, 16.1, p=0.046), and the length of hospital stay was 18.5 days (95% CI 17.0, 20.0, p=0.042) in the QARP group, both of which were significantly reduced compared with the standard therapies group (p<0.05).
CONCLUSION
QARP plus standard therapies improved lung function and symptoms such as dyspnea and cough in patients with severe COVID-19 and shortened the length of hospital stay. Therefore, QARP may be considered an effective treatment option for patients with severe COVID-19.
TRIAL REGISTRATION
Clinical Research Information Service Identifier: ChiCTR2000029994.
背景
对于重症 COVID-19 患者，有多种有效的补充和综合疗法。该试验旨在评估气功锻炼和穴位按摩康复方案（QARP）治疗重症 COVID-19 患者的疗效和优势。
方法
共招募了 128 名年龄在 20 至 80 岁之间的 COVID-19 患者，并按 1:1 的比例随机分配，分别接受 QARP 联合标准疗法或仅接受标准疗法。QARP 包括穴位按摩疗法和气功锻炼（）。主要结局采用改良医学研究理事会（mMRC）呼吸困难量表进行测量，次要结局包括改良博格呼吸困难量表（MBS）、疲劳量表 -14（FS-14）、患者健康问卷 -9 量表（PHQ-9）、呼吸道症状持续时间和生命体征。
结果
共有 128 名患者完成了临床试验。与基线相比，QARP 组和标准疗法组在生命体征（血压除外）和临床量表方面均有显著改善（p<0.05）。QARP 组在 mMRC 呼吸困难量表（-1.8 [-2.1, -1.6]，p = 0.018）和改良博格呼吸困难量表（-3.7 [95% 置信区间（CI）-4.3, -3.1]，p = 0.045）方面也显示出更显著的改善。QARP 组咳嗽持续时间为 14.3 天（95% CI 12.6, 16.1，p = 0.046），住院时间为 18.5 天（95% CI 17.0, 20.0，p = 0.042），与标准疗法组相比均显著缩短（p<0.05）。
结论
QARP 联合标准疗法可改善重症 COVID-19 患者的肺功能以及呼吸困难和咳嗽等症状，并缩短住院时间。因此，QARP 可被视为重症 COVID-19 患者的一种有效治疗选择。
试验注册
临床研究信息服务标识符：ChiCTR2000029994。
Zotero 插件